Last $5.98 USD
Change Today +0.02 / 0.34%
Volume 12.3K
CPIX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

cumberland pharmaceuticals (CPIX) Snapshot

Open
$5.95
Previous Close
$5.96
Day High
$6.15
Day Low
$5.93
52 Week High
12/26/14 - $6.20
52 Week Low
05/8/14 - $4.20
Market Cap
103.8M
Average Volume 10 Days
21.7K
EPS TTM
$0.02
Shares Outstanding
17.4M
EX-Date
--
P/E TM
299.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for CUMBERLAND PHARMACEUTICALS (CPIX)

cumberland pharmaceuticals (CPIX) Related Bloomberg News

View More Bloomberg News

cumberland pharmaceuticals (CPIX) Related Businessweek News

No Related Businessweek News Found

cumberland pharmaceuticals (CPIX) Details

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States. The company’s principal products comprise Acetadote, an intravenous formulation of N-acetylcysteine indicated for the treatment of acetaminophen poisoning; Caldolor, an intravenous formulation of ibuprofen for the treatment of pain and fever; and Kristalose, a prescription laxative administered orally for the treatment of constipation. Its products also include Omeclamox-Pak, a triple therapy combination medication for the treatment of Helicobacter pylori infection and duodenal ulcer disease; and Hepatoren injection, which is in Phase II clinical development for the treatment of hepatorenal syndrome. The company markets and sells its products through sales representatives and managers. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

96 Employees
Last Reported Date: 03/11/14
Founded in 1999

cumberland pharmaceuticals (CPIX) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $620.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $297.0K
Chief Development Officer and Senior Vice Pre...
Total Annual Compensation: $392.3K
Chief Commercial Officer, Senior Vice Preside...
Total Annual Compensation: $312.1K
Chief Compliance Officer and Vice President o...
Total Annual Compensation: $227.5K
Compensation as of Fiscal Year 2013.

cumberland pharmaceuticals (CPIX) Key Developments

Cumberland Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Cumberland Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net loss attributable to common shareholders of $745,920 or $0.04 per basic and diluted share on net revenues of $9,729,047 compared to net loss attributable to common shareholders of $819,942 or $0.04 per basic and diluted share on net revenues of $6,528,575 reported a year ago. Operating income was $989,038 compared to operating loss of $1,514,768 reported a year ago. Income before income taxes was $1,070,166 compared to loss before income taxes of $1,518,704 reported a year ago. For the nine months, the company reported net loss attributable to common shareholders of $1,754,810 or $0.10 per basic and diluted share on net revenues of $27,572,459 compared to net loss attributable to common shareholders of $604,251 or $0.03 per basic and diluted share on net revenues of $23,867,795 reported a year ago. Operating income was $2,612,698 compared to operating loss of $1,329,261 reported a year ago. Income before income taxes was $2,766,232 compared to loss before income taxes of $1,230,273 reported a year ago. Net cash provided by operating activities was $3,957,854 compared to $938,761 reported a year ago. Additions to property and equipment were $150,387 compared to $92,435 reported a year ago.

Cumberland Pharmaceuticals, Inc. to Report Q3, 2014 Results on Nov 04, 2014

Cumberland Pharmaceuticals, Inc. announced that they will report Q3, 2014 results at 4:30 PM, US Eastern Standard Time on Nov 04, 2014

Cumberland Pharmaceuticals, Inc., Q3 2014 Earnings Call, Nov 04, 2014

Cumberland Pharmaceuticals, Inc., Q3 2014 Earnings Call, Nov 04, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPIX:US $5.98 USD +0.02

CPIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $43.00 USD 0.00
Durect Corp $0.92 USD 0.00
Ironwood Pharmaceuticals Inc $16.67 USD +0.01
Pacira Pharmaceuticals Inc/DE $106.47 USD 0.00
Sucampo Pharmaceuticals Inc $15.97 USD 0.00
View Industry Companies
 

Industry Analysis

CPIX

Industry Average

Valuation CPIX Industry Range
Price/Earnings 100.0x
Price/Sales 2.9x
Price/Book 1.3x
Price/Cash Flow 63.7x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CUMBERLAND PHARMACEUTICALS, please visit www.cumberlandpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.